Latest Distribution News

Decidr AI Industries reported a sharp quarterly fall in its invoicing-based AER, even as customer receipts reached a record and Sugarwork’s qualified pipeline expanded. The company is relying on A$11 million of annualised cost reductions and upcoming product launches to extend its runway and convert enterprise interest into recurring revenue.

OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.

Way2VAT is betting that its new Way2Invoice platform, Coupa distribution and Go-Global partnership can convert product momentum into recurring revenue, while a 15% cost reduction begins to address ongoing cash burn. Quarterly revenue was broadly flat at A$1.90 million, with A$3.05 million in cash and A$5.20 million of debt drawn at quarter end.

Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.

Antilles Gold remains largely stalled in Cuba after its joint venture was designated a US Specially Designated National, with only site security continuing at Nueva Sabana. A conditional GEM deal could bring US$18 million and a path towards sanction relief, but the company ended September with just US$882,000 in cash.

Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.

Jupiter Mines delivered Tshipi production and sales ahead of plan in the September quarter, but weaker manganese prices, higher freight and lower sales volumes sharply reduced earnings. Attributable cash fell to A$52.7 million after dividends and working capital outflows.

Novatti’s AU/NZ quarterly transaction value rose to $1.2 billion, but regulatory disruption to international BPAY payments pushed revenue lower and left Cash EBITDA negative. The company is targeting an early 2027 relaunch while relying on pipeline conversion and product mix improvements to support its next phase of growth.

Gratifii says its largest enterprise quarter has put Qantas, Woolworths MarketPlus and other major loyalty programs onto its expanding rewards marketplace. The commercial reach is significant, but the update leaves transaction volumes, margins and cash contribution largely unquantified.

Doctor Care Anywhere’s Q3 revenue rose 16% to £11.3 million as its weight-management business delivered its first full quarter, lifting subscription revenue to 19% of the total. The unaudited update also shows modest consultation growth, higher cash and three new distribution partnerships.

Barramundi’s portfolio suffered its worst reported year in decades, with a NZ$42.9 million loss and an adjusted NAV return of -18.2% against a 9.2% benchmark gain. The board is negotiating a new management agreement with Fisher Funds while imposing tighter diversification and risk limits.

Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.